Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation

BayerBayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer's investigational macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting - taking place from November 26 to 30, 2023, in Chicago, USA. Bayer also announced the results of a recently published paper on the cost effectiveness of supplemental screening methods for women with dense breasts in the U.S., to provide greater certainty around the clinical and economic benefits of supplemental screening methods. In addition, Bayer announced four collaboration agreements with the aim to further expand the offering on its medical imaging platform Calantic™ Digital Solutions.

The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to address today’s industry challenges and accelerate innovation for the benefit of patients and their clinicians, including harnessing the vast potential of artificial intelligence (AI).

Fostering innovation in Radiology AI

In more than 30 panel discussions, Bayer's AI team composed jointly of experts from both Calantic™ Digital Solutions and Blackford Analysis as well as external thought leaders, will share insights to help healthcare providers, hospital administrators and developers advance their AI strategy, discussing topics like regulatory challenges in the field of AI in medical imaging, app selection, and how to leverage clinical utility frameworks to assess return on investment (ROI). Partner companies from both Bayer and Blackford will present various app approaches and solutions.

While Blackford provides infrastructure and access to a rich clinical application (ClinApp) ecosystem focused on imaging and analytics, Bayer’s own platform Calantic™ Digital Solutions which is building on technology from Blackford and adding additional workflow and analytics components, delivers access to applications for medical imaging, including those enabled by AI - coming with the value proposition to support diagnosis and increase the throughput of medical imaging examinations. On the occasion of RSNA 2023, Bayer also announced that it will partner with radiology AI technology providers Perspectum Limited, Brainomix Limited, Qure.ai, and Imagine Software - with the aim to further expand the offering on its medical imaging platform CalanticTM Digital Solutions.

In addition, Bayer is offering various tech talks, including pilot "Spark Tank Sessions" where app companies at an early stage can learn new ways to refine their value proposition, and get feedback such as optimal workflow and commercialization pathways from an expert panel. Calantic SPARK, Bayer’s accelerator program for medical imaging app developers to further foster innovation in radiology AI, will showcase its partners Imagine Software (Within Health) and Scanslated. Bayer's Calantic SPARK is a targeted program to help radiology AI startups of all stages get to market faster by offering advice spanning medical, regulatory, reimbursement expertise, and market access - thereby enabling commercialization and distribution through Calantic™ Digital Solutions.

Blackford, the global strategic AI platform and solutions provider that was acquired by Bayer under the well-established company’s arm’s length model, continues to expand its AI portfolio and global strategic relationships in advance of RSNA. The AI portfolio available via the Blackford Platform now includes over 100 applications from 40 separate partner vendors. Blackford has also recently entered into partnerships with global medical imaging provider Philips, healthcare interoperability provider Rhapsody and enterprise imaging provider Mach7 to support their respective journeys into AI solution provision.

Taking a glimpse at a radiology clinic of the future

Reflecting Bayer's overall RSNA 2023 theme "Let's Envision the Future of Radiology", the Experience Center at Bayer’s main booth (#2519) will offer visitors an immersive tour through a radiology clinic of the future. Here they can discover the company's digital, integrated, disease-oriented solutions across the entire radiology workflow - through the eyes of a patient. The Experience Center includes 21 different stations along the journey, each with interactive content, including Augmented Reality (AR).

About Radiology at Bayer

As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence - from innovative products to high-quality services - to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by Artificial Intelligence (AI). Bayer's radiology products generated close to €2bn sales in 2022. Based on the company’s ambition to outperform the radiology market’s average annual growth rate of 5 percent by 2030, Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction - from diagnosis to care.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Most Popular Now

Transforming Drug Discovery with AI

A new AI-powered program will allow researchers to level up their drug discovery efforts. The program, called TopoFormer, was developed by an interdisciplinary team led by Guowei Wei, a Michigan...

We may Soon be Able to Detect Cancer wit…

A new paper in Biology Methods & Protocols, published by Oxford University Press, indicates that it may soon be possible for doctors to use artificial intelligence (AI) to detect and...

Maternity Tech Launched to Help NHS Meas…

Health tech provider C2-Ai has formally launched a new 'observatory' system to help hospitals gain a better understanding of risks, outcomes and safety within maternity and neonatal services. Announced at the...

Large Language Models Illuminate a Progr…

This study is led by Prof. Bin Dong (Beijing International Center for Mathematical Research, Peking University) and Prof. Lin Shen (Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational...

Health Innovation East Partners with Cog…

Health Innovation East, the innovation arm of the NHS in the East of England and Cogniss, a no-code ecosystem for digital health solutions, have announced a strategic partnership to launch...

An AI-Powered Wearable System Tracks the…

Scientists at the University of Southern California have developed an artificial intelligence (AI)-powered system to track tiny devices that monitor markers of disease in the gut. Devices using the novel...

"Self-Taught" AI Tool Helps to…

A computer program based on data from nearly a half-million tissue images and powered by artificial intelligence (AI) can accurately diagnose cases of adenocarcinoma, the most common form of lung...

New Computational Model of Real Neurons …

Nearly all the neural networks that power modern artificial intelligence (AI) tools such as ChatGPT are based on a 1960s-era computational model of a living neuron. A new model developed...

Meet CARMEN, a Robot that Helps People w…

Meet CARMEN, short for Cognitively Assistive Robot for Motivation and Neurorehabilitation - a small, tabletop robot designed to help people with mild cognitive impairment (MCI) learn skills to improve memory...

AI Matches Protein Interaction Partners

Proteins are the building blocks of life, involved in virtually every biological process. Understanding how proteins interact with each other is crucial for deciphering the complexities of cellular functions, and...

AI Model to Improve Patient Response to …

A new artificial intelligence (AI) tool that can help to select the most suitable treatment for cancer patients has been developed by researchers at The Australian National University (ANU). DeepPT, developed...

Mobile Phone Data Helps Track Pathogen S…

A new way to map the spread and evolution of pathogens, and their responses to vaccines and antibiotics, will provide key insights to help predict and prevent future outbreaks. The...